Targeting cell death: helping push cancer cell... - CLL Support

CLL Support

24,067 members40,937 posts

Targeting cell death: helping push cancer cells over the edge

Jm954 profile image
Jm954Administrator
8 Replies

The BCL-2 family regulate one of the body’s apoptotic pathways. As scientists understand more about these proteins, they are able to push the boundaries of cancer research.

The BCL-2 family is broadly divided into two types: pro-survival proteins, including BCL-2, BCL-XL, BCL-W and MCL-1, which help keep the cell alive; and pro-apoptotic proteins, which promote cell death. These two types of BCL-2 proteins typically work together to regulate apoptosis.

More about how AbbVie engineered a new drug to target both BCL-2 and BCL-XL which might be helpful for us CLLers here:

nature.com/articles/d42473-...

Note this is an AbbVie advert for their research in the journal Nature

Jackie

Written by
Jm954 profile image
Jm954
Administrator
To view profiles and participate in discussions please or .
Read more about...
8 Replies
Justasheet1 profile image
Justasheet1

Jackie,

Sounds like it doesn’t leave any room for resistance to develop.

Jeff

Murzik profile image
Murzik

Great article!!! And a lot of hope of using proteins of BCL2 group as future cancer fighting targets. Thank you, G.

AussieNeil profile image
AussieNeilPartnerAdministrator

Per reference 8, the first drug that inhibited both BCL-2 and BCL-XL was ABT-263, later named Navitoclax;

en.m.wikipedia.org/wiki/Nav...

The last CLL patient on the Naviclax trial developed resistance to the trial drug only last year.

Per reference 10, the second, more selective drug for BCL-2 is ABT-199, later named Venetoclax.

Neil

Justasheet1 profile image
Justasheet1 in reply toAussieNeil

Neil,

So what happened to Naviclax, do you know?

Jeff

AussieNeil profile image
AussieNeilPartnerAdministrator in reply toJustasheet1

There is an expanded access program

clinicaltrials.gov/ct2/show...

I expect that it's largely been superseded by the much more selective Venetoclax and yet another of the many failed drugs, which at least led to a very effective drug.

Neil

Wroxham profile image
Wroxham

Thanks Jackie.

Sue

Smakwater profile image
Smakwater

Very cool read Jackie,

Hence the BCL-2 inhibitor venclexta.

I read something like this and it makes me ponder how there are some who claim to be bored.

Fascinating,

JM

Jm954 profile image
Jm954Administrator in reply toSmakwater

yes, it stretches your mind both comprehension and imagination - brilliant!

Jackie

Not what you're looking for?

You may also like...

Time from the first cancer cell to first symptoms?

Most of us learnt about CLL suspicion after a blood check which showed elevated white blood cell...
mantana profile image

"Whole bacterial" pneumonia vaccine approaches human trials

"Professor James Paton, a director at GPN Vaccines and Director of the University of Adelaide's...
AussieNeil profile image
Partner

B cell lymphoma lumps

I was just reviewing a post about a P cell lymphoma that someone had in there neck or upper lower...
skipro profile image

Fascinating: Development of Venetoclax

For a few years, I've taken a breather from HU while focusing on full life rather than my CLL. I'm...
starsafta profile image

CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction

DART (rather than CART) treatment could be come important in the future, especially for CLL where...
Jm954 profile image
Administrator

Moderation team

See all
SofiaDeo profile image
SofiaDeoAdministrator
Newdawn profile image
NewdawnAdministrator
AussieNeil profile image
AussieNeilAdministrator

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.